NCT02663518 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 107
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 40
- group Id
- BG007
- value
- 42
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 6
- group Id
- BG011
- value
- 3
- units
- Participants
- groups
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 milligram per kilogram (mg/kg) infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG000
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG001
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG002
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG003
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg
- description
- Participants with a broader variety of hematologic malignancies and selected solid tumors, received a 0.2 mg/kg/week TTI-621 infusion until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG004
- title
- Part 2: Ontorpacept (PF-07901800/TTI-621) Monotherapy
- description
- Participants with cHL received 0.1 mg/kg/week TTI-621 infusion along with 3 mg/kg nivolumab given every 2 weeks or a fixed dose per current FDA approved package insert for cHL.If required dose of TTI-621 could be increased up to 0.5 mg/kg/week. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.
- id
- BG005
- title
- Part 2: Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination
- description
- Participants with CD20-positive malignancies received 0.1 mg/kg/week TTI-621 infusion along with 375 mg/m\^2 rituximab given weekly (1 cycle) for up to 8 cycles according to the institutional standard of care. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.
- id
- BG006
- title
- Part 2: Ontorpacept (PF-07901800/TTI-621) + Rituximab Combination
- description
- Participants with CTCL and PTCL, received a 0.2 mg/kg/week TTI-621 infusion. Initial 2 weeks of 0.2 mg/kg treatment followed by intraparticipant dose intensification at an increment of 0.1 mg/kg per week up to 0.5 mg/kg within 5-8 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG007
- title
- Part 3: Ontorpacept (PF-07901800/TTI-621) Monotherapy
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG008
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG009
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG010
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG011
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 52
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 19
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 0
- title
- < 65 Years
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 36
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 11
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 2
- title
- 65 - < 75 Years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 19
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 1
- title
- 75 - < 85 Years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- >= 85 Years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 46
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 18
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 61
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 30
- group Id
- BG007
- value
- 24
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 3
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 94
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 34
- group Id
- BG007
- value
- 32
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 3
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 85
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 31
- group Id
- BG007
- value
- 30
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 3
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Analysis population included all the participants who received at least one dose of study treatment.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 107
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 40
- group Id
- BG007
- value
- 42
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 6
- group Id
- BG011
- value
- 3
- units
- Participants
- groups
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 milligram per kilogram (mg/kg) infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG000
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG001
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG002
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG003
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg
- description
- Participants with a broader variety of hematologic malignancies and selected solid tumors, received a 0.2 mg/kg/week TTI-621 infusion until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG004
- title
- Part 2: Ontorpacept (PF-07901800/TTI-621) Monotherapy
- description
- Participants with cHL received 0.1 mg/kg/week TTI-621 infusion along with 3 mg/kg nivolumab given every 2 weeks or a fixed dose per current FDA approved package insert for cHL.If required dose of TTI-621 could be increased up to 0.5 mg/kg/week. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.
- id
- BG005
- title
- Part 2: Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination
- description
- Participants with CD20-positive malignancies received 0.1 mg/kg/week TTI-621 infusion along with 375 mg/m\^2 rituximab given weekly (1 cycle) for up to 8 cycles according to the institutional standard of care. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.
- id
- BG006
- title
- Part 2: Ontorpacept (PF-07901800/TTI-621) + Rituximab Combination
- description
- Participants with CTCL and PTCL, received a 0.2 mg/kg/week TTI-621 infusion. Initial 2 weeks of 0.2 mg/kg treatment followed by intraparticipant dose intensification at an increment of 0.1 mg/kg per week up to 0.5 mg/kg within 5-8 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG007
- title
- Part 3: Ontorpacept (PF-07901800/TTI-621) Monotherapy
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG008
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG009
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG010
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- BG011
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 52
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 19
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 0
- title
- < 65 Years
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 36
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 11
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 2
- title
- 65 - < 75 Years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 19
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 1
- title
- 75 - < 85 Years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- >= 85 Years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 46
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 18
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 61
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 30
- group Id
- BG007
- value
- 24
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 3
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 94
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 34
- group Id
- BG007
- value
- 32
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 3
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 85
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 31
- group Id
- BG007
- value
- 30
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 3
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Analysis population included all the participants who received at least one dose of study treatment.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle